# Venus Medtech acquires Cardiovalve for $300 million

Venus Medtech (Hangzhou) Inc. announced the acquisition of 100% equity interest in Cardiovalve Ltd., a transcatheter mitral and tricuspid valve treatment company, for a consideration of $300 million. The acquisition aims to expand Venus Medtech's product pipeline in mitral and tricuspid valve replacement.

- Type: Acquisition
- Announced: 2021-12-07
- Value: $300.0M
- Status: announced
- Products: transcatheter mitral valve replacement system, transcatheter tricuspid valve replacement system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Venus Medtech](https://endata.com/companies/34506.md) (acquirer)
- [Cardiovalve](https://endata.com/companies/59531.md) (target)

## Sources

- [newswire.ca](https://www.newswire.ca/fr/news-releases/venus-medtech-acquires-cardiovalve-to-optimize-its-innovative-products-pipeline-of-mitral-and-tricuspid-valve-replacement-860609673.html), 2021-12-08: "Venus Medtech will acquire 100% equity interest and corresponding equity at a consideration of $300 million, and will pay the consideration conditionally in installments subject to the completion of certain milestone events as agreed."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.